149 related articles for article (PubMed ID: 11468201)
21. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
Holmes LE; Gupta R; Rajendran S; Luu J; French JK; Juergens CP
Cardiovasc Ther; 2016 Oct; 34(5):330-6. PubMed ID: 27327862
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function.
Gretler DD; Guerciolini R; Williams PJ
Clin Ther; 2004 Mar; 26(3):390-8. PubMed ID: 15110131
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.
Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators
N Engl J Med; 1998 Aug; 339(7):436-43. PubMed ID: 9705684
[TBL] [Abstract][Full Text] [Related]
24. Spotlight on eptifibatide in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.
Curran MP; Keating GM
BioDrugs; 2006; 20(1):63-5. PubMed ID: 16573353
[TBL] [Abstract][Full Text] [Related]
25. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention.
Harrington RA; Kleiman NS; Kottke-Marchant K; Lincoff AM; Tcheng JE; Sigmon KN; Joseph D; Rios G; Trainor K; Rose D
Am J Cardiol; 1995 Dec; 76(17):1222-7. PubMed ID: 7503000
[TBL] [Abstract][Full Text] [Related]
26. Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial.
Puma JA; Banko LT; Pieper KS; Sacchi TJ; O'Shea JC; Dery JP; Tcheng JE
J Am Coll Cardiol; 2006 Feb; 47(4):715-8. PubMed ID: 16487833
[TBL] [Abstract][Full Text] [Related]
27. Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.
Curran MP; Keating GM
Drugs; 2005; 65(14):2009-35. PubMed ID: 16162023
[TBL] [Abstract][Full Text] [Related]
28. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
Hobbach HP; Schuster P
Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467
[TBL] [Abstract][Full Text] [Related]
29. Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial.
Schulman SP; Goldschmidt-Clermont PJ; Topol EJ; Califf RM; Navetta FI; Willerson JT; Chandra NC; Guerci AD; Ferguson JJ; Harrington RA; Lincoff AM; Yakubov SJ; Bray PF; Bahr RD; Wolfe CL; Yock PG; Anderson HV; Nygaard TW; Mason SJ; Effron MB; Fatterpacker A; Raskin S; Smith J; Brashears L; Gottdiener P; du Mee C; Kitt MM; Gerstenblith G
Circulation; 1996 Nov; 94(9):2083-9. PubMed ID: 8901655
[TBL] [Abstract][Full Text] [Related]
30. Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty.
Akkerhuis KM; van Den Brand MJ; van Der Zwaan C; Peels HO; Suryapranata H; van Der Wieken LR; Stibbe J; Hoffmann J; Baardman T; Deckers JW; Simoons ML
Heart; 2001 Apr; 85(4):444-50. PubMed ID: 11250974
[TBL] [Abstract][Full Text] [Related]
31. A randomized trial comparing eptifibatide vs. placebo in patients with diffuse coronary artery disease undergoing drug-eluting stent implantation: design of the INtegrilin plus STenting to Avoid myocardial Necrosis Trial.
Biondi-Zoccai GG; Valgimigli M; Sheiban I; Margheri M; Marzocchi A; Prati F; Vischi M; Lettieri C; Violini R; Sardella G; Stabile A; Clementi F; Romeo F; Colombo A; Sangiorgi G
J Cardiovasc Med (Hagerstown); 2008 Sep; 9(9):957-62. PubMed ID: 18695440
[TBL] [Abstract][Full Text] [Related]
32. Comparative antithrombotic effects of magnesium sulfate and the platelet glycoprotein IIb/IIIa inhibitors tirofiban and eptifibatide in a canine model of stent thrombosis.
Rukshin V; Shah PK; Cercek B; Finkelstein A; Tsang V; Kaul S
Circulation; 2002 Apr; 105(16):1970-5. PubMed ID: 11997285
[TBL] [Abstract][Full Text] [Related]
33. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
Gurbel PA; Bliden KP; Zaman KA; Yoho JA; Hayes KM; Tantry US
Circulation; 2005 Mar; 111(9):1153-9. PubMed ID: 15738352
[TBL] [Abstract][Full Text] [Related]
34. High-dose, single-bolus eptifibatide: a safe and cost-effective alternative to conventional glycoprotein IIb/IIIa inhibitor use for elective coronary interventions.
Fischell TA; Attia T; Rane S; Salman W
J Invasive Cardiol; 2006 Oct; 18(10):487-91. PubMed ID: 17042093
[TBL] [Abstract][Full Text] [Related]
35. Variability in extent of platelet function inhibition after administration of optimal dose of glycoprotein IIb/IIIa receptor blockers in patients undergoing a high-risk percutaneous coronary intervention.
Danzi GB; Capuano C; Sesana M; Mauri L; Sozzi FB
Am J Cardiol; 2006 Feb; 97(4):489-93. PubMed ID: 16461043
[TBL] [Abstract][Full Text] [Related]
36. Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.
Mandak JS; Blankenship JC; Gardner LH; Berkowitz SD; Aguirre FV; Sigmon KN; Timmis GC; Gilchrist IC; McIvor M; Resar J; Weiner BH; George BS; Talley JD; Lincoff AM; Tcheng JE; Califf RM; Topol EJ
J Am Coll Cardiol; 1998 Jun; 31(7):1518-24. PubMed ID: 9626829
[TBL] [Abstract][Full Text] [Related]
37. Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial.
Dery JP; Campbell ME; Mathias J; Pieper KS; Harrington RA; Madan M; Gibson CM; Tolleson TR; O'Shea JC; Tcheng JE;
Catheter Cardiovasc Interv; 2007 Jul; 70(1):43-50. PubMed ID: 17203469
[TBL] [Abstract][Full Text] [Related]
38. Stent parameters predict major adverse clinical events and the response to platelet glycoprotein IIb/IIIa blockade: findings of the ESPRIT trial.
Tcheng JE; Lim IH; Srinivasan S; Jozic J; Gibson CM; O'Shea JC; Puma JA; Simon DI
Circ Cardiovasc Interv; 2009 Feb; 2(1):43-51. PubMed ID: 20031692
[TBL] [Abstract][Full Text] [Related]
39. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD
Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633
[TBL] [Abstract][Full Text] [Related]
40. Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
Lauer MA; Houghtaling PL; Peterson JG; Granger CB; Bhatt DL; Sapp SK; Simoons ML; Harrington RA; Topol EJ; Lincoff AM;
Circulation; 2001 Dec; 104(23):2772-7. PubMed ID: 11733393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
